Attributing fatal cardiac effects to methadone: What's the evidence?

Journal of Addictive Diseases

Volumn 27, Issue 4, 2008, Pages 1-4

  Newman, Robert G ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE; NARCOTIC ANALGESIC AGENT;

AUTOPSY; CARDIOTOXICITY; CAUSE OF DEATH; CHRONIC PAIN; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG OVERDOSE; DRUG WITHDRAWAL; EDITORIAL; FATALITY; HEART ARREST; HUMAN; METHADONE TREATMENT; MORTALITY; OPIATE ADDICTION; QT PROLONGATION; SIDE EFFECT; SUDDEN DEATH; TORSADE DES POINTES; UNITED STATES; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; FOOD AND DRUG ADMINISTRATION; NOTE;

ANALGESICS, OPIOID; CARDIOVASCULAR DISEASES; HUMANS; METHADONE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 63249083861     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1080/10550880802324275     Document Type: Editorial

References (22)

1. Chugh SS, Socoteanu C, Reinier K, Waltz J, Jui J, Gunson K. A community-based evaluation of sudden death associated with therapeutic levels of methadone. Am J Med. 2008;121:66-71.
2. Substance Abuse and Mental Health Services Administration. Methadone Associated mortality: report of a national assessment. [updated 2004; cited 2008 April 1]. Available from: www.samhsa.gov.
3. Shields LBE, Hunsaker III JC, Corey TS, Ward MK, Stewart D. Methadone toxicity fatalities: a review of medical examiner cases in a large metropolitan area. J Forensic Sci. 2007;52:1389-95.
4. Fuller BE, Rieckmann TR, McCarty DJ, Ringor-Carty R, Kennard S. Elimination of methadone benefits in the Oregon health plan and its effects on patients. Psychiatr Serv. 2006;57:686-91.
5. Ballesteros MF, Sanford CP, Gilchrist J, Agyekum GA, Butts J. Increase in deaths due to methadone in North Carolina. JAMA. 2003;290:40.
6. Williamson PA, Foreman KJ, White JM, Anderson G. Methadone-related overdose deaths in South Australia, 1984-1994. Med J Austral. 1997;166:302-5.
7. Physicians' Desk Reference. 56th ed. Montvale, NJ: Medical Economics Co. 2002;p. 3057.
8. Reisine T, Pasternak G. Opioid analgesics and antagonists. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996: p. 537.
9. Code of Federal Regulations. Federal opioid treatment standards. 2002. 42 CFR 8.12(h)(3)(ii).
10. U.S. Food and Drug Administration. Methadone use for pain control may result in death and life-threatening changes in breathing and heart beat. [updated 2006; cited 2008 April 2]. Available from: http://www.fda.gov/CDER/ drug/advisory/methadone.htm.
11. U.S. Food and Drug Administration. methadone use for pain control may result in death and life-threatening changes in breathing and heart beat. [updated 2006; cited 2008 April 2]. Available from: http://www.fda.gov/CDER/ drug/advisory/methadone.htm.
12. Roxane Laboratories Inc. Dolophine Hydrochloride CII. [updated 2006; cited 2008 April 2]. Available from: www.fda.gov/cder/foi/label/2006/ 006134s028lbl.pdf.
13. Methadone Alert. JAMA. 2007;297:354.
14. Belluck P. Methadone suddenly grows as a killer drug. New York Times. February 9, 2003; p. 1.
15. ABC News. Even in normal doses, methadone can kill. [updated 2008 January 22; cited 2008 April 2]. Available from: http://abcnews.go.com/Health/ PainManagement/ wireStory?id=4172607.
16. USA. Plötzliche Todesfälle durch Methadon. [updated 2008 January 16; cited 2008 April 2]. Available from: http://www.aerzteblatt- studieren.de/doc.asp?docId= 107131.
17. Pearson EC, Woosley RL. QT prolongation and tor-sades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Safe. 2005;14:747-53.
18. Maremmani I, Pacini M, Cesaroni C, Lovrecic M, Perugi G, Tagliamonte A. QTc interval prolongation in patients in long-term methadone maintenance therapy. Eur Addict Res. 2005;11:44-9.
19. Martell BA, Arnstein JH, Krantz MJ, Gourevitch MN. Impact of methadone treatment on cardiac repolar-ization and conduction in opioid users. Am J Cardiol. 2005;95:915-8.
20. Krantz MJ, Lewkowiez L, Hays H, Woodroffe A, Robertson AD, Mehler PS. Torsade de pointes associated with very-high-dose methadone. Ann Int Med. 2003;137: 501-4.
21. Krantz M. Heterogenous impact of methadone on the QTc interval: what are the practical implications? J Addict Dis. 2008;27(4):5-9.
22. College of Physicians and Surgeons of Ontario. Methadone maintenance guidelines. [updated 2005; cited 2008 June 15]. Available from: http://www.cpso.on.ca/ publications/methguidenov05.htm.